Clinical Trial Update: A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung [Phase 1]

View source ↗

Summary

Phase I/Ib study evaluating the MEK1/2 inhibitor binimetinib (MEK162) in combination with carboplatin and pemetrexed in patients with non-squamous non-small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed) (pemetrexed)
• CARBOPLATIN (Carboplatin)
• Mektovi (binimetinib) (binimetinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Lungcancer | Phase 1 | Status: COMPLETED | Results posted: 2025-08-21